Objective Glucocorticoid (GC) 
Introduction

Glucocorticoids (GC) are used to treat autoimmune, neurological, dermatological and respiratory diseases, and their anti-inflammatory effects are effective for treating various diseases; however, GC treatment is greatly limited by its various serious side effects, which are dependent on the dose and duration of GC (1). Although the side effects of GC include immunodysfunction and osteoporotic fractures, various metabolic abnormalities can occur, such as the development of central adiposity, hepatic steatosis, dyslipidemia, increased breakdown of skeletal muscle mass and glucose intolerance (2). As for GC and glucose metabolism, GC excess increases insulin resistance by affecting the muscles as well as the liver and partly through the suppression of insulin secretion, resulting in glucose intolerance or secondary diabetes mellitus in susceptible patients (2). The frequency of glucose intolerance or diabetes is high in GCtreated patients or patients with Cushing's syndrome (3); however, few prospective studies have examined the change in glucose metabolism in newly GC-treated patients.
On the other hand, GC excess is related to an increase in serum lipid levels, especially total cholesterol (Total CHOL) 
T a b l e 1 . P a t i e n t P r o f i l e s i n GC-t r e a t e d P a t i e n t s
Subjects and Methods
Patients and study protocol
Thirty-four patients (14 men and 20 women) 
Results
Patient profiles
The clinical characteristics and baseline data of GCtreated patients are shown in Table 1 . Baseline data of all glucose and lipid metabolism were not significantly different among groups. 
F i g u r e 2 . E f f e c t s o f v a r i o u s GC r e g i me n s o n F P G, I RI a n d HOMA-R. F P G, s e r u m I RI a n d HOMA-R l e v e l s we r e f o l l o we d a t d a y s 3 , 7 , 1 4 , 2 8 a n d mo n t h 3 i n p a t i e n t s wi t h GC t r e a t me n t . P : p u l s e t h e r a p y , H: P S L a t d o s e s ≥ 4 0 mg / d a y , M: P S L a t d o s
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Short-term changes in glucose metabolism parameters
First, we examined the short-term changes in FPG, IRI and HOMA-R in all GC-treated patients. As shown in Fig. 1 Fig. 2 (Fig. 2) . Interestingly, a transient peak on day 3 in IRI and HOMA-R levels was also observed only in groups P and H (Fig. 2) ; however, the continuous increases after day 7 of IRI and HOMA-R levels seemed to be maintained in all groups. Fig. 3 
. A transient elevation in FPG level on day 3 was observed only in groups P and H
Short-term changes in lipid metabolism parameters
Next, we examined the short-term changes in serum T-CHOL, TG, HDL-CHOL and LDL-CHOL levels in all GCtreated patients. As shown in
, T-CHOL and LDL-CHOL levels increased on day 3 of PSL administration and similar levels were maintained after day 7. HDL-CHOL levels significantly increased on day 3, and then progressively increased from days 3 to day 28. TG levels did not change during treatment. Differences among groups P, H, M and S were analyzed as shown in Figs. 4 & 5. No relationship between the GC dose and changes in each lipid parameter seemed to exist.
F i g u r e 3 . S h o r t -t e r m e f f e c t s o f GC t h e r a p y o n l i p i d met a b o l i s m p a r a me t e r s . S e r u m l e v e l s o f T -CHOL , T G, HDL -CHOL a n d L DL -CHOL we r e f o l l o we d o n d a y s 3 , 7 , 1 4 , 2 8 a n d a t mo n t h 3 i n p a t i e n t s wi t h GC t r e a t me n t . * p < 0 . 0 5 , * * p < 0 . 0 1 , c o mp a r e d t o e a c h b a s e l i n e l e v e l .
F i g u r e 4 . E f f e c t s o f v a r i o u s GC r e g i me n s o n T -CHOL a n d T G S e r u m l e v e l s o f T -CHOL a n d T G we r e f o l l o we d o n d a y s 3 , 7 , 1 4 , 2 8 a n d a t mo n t h 3 i n p a t i e n t s wi t h GC t r e a t me n t . P : p u l s e t h e r a p y , H: P S L a t d o s e s ≥ 4 0 mg / d a y , M: P S L a t d o s
Discussion
Several reports have indicated that FPG and IRI levels were increased in patients with Cushing's syndrome or treated with GC (3).
In clinical studies, glucose metabolism abnormality by GC excess is mainly considered to be due to increased insulin resistance in tissues after GC exposure (8) (9) (10) . Insulin intolerance is derived from the inhibition of glucose uptake in muscle tissues, gluconeogenesis in the liver, and inhibition of insulin signaling in cells (2) . On the other hand, GC impairs insulin secretion in vitro (2) . Acute administration of GC impairs insulin secretion in healthy volunteers (11) (12) (13) (8, 9, (14) (15) (16) (17) . These findings suggest that chronic GC excess might impair insulin secretion secondary to enhanced insulin resistance in patients with subclinical insulin secretion impairment.
Several studies have reported that elevation of FPG and serum IRI are observed in the early phase of GC administration (8, 9, (14) (15) (16) (17) . In the present data, FPG was transiently increased at day 3 after GC treatment initiation, and then it returned to the normal range after day 7. Serum IRI level was increased at day 3, and then somewhat returned to the lower level, but was still significantly higher at day 7 d o n d a y s 3 , 7 , 1 4 , 2 8 a n d a t (26) . In addition, GC may stimulate liver production of nascent HDL (27) 
mo n t h 3 i n p a t i e n t s wi t h GC t r e a t me n t . P : p u l s e t h e r a p y , H: P S L a t d o s
